Literature DB >> 14706090

Relationship between ciprofloxacin resistance and extended-spectrum beta-lactamase production in Escherichia coli and Klebsiella pneumoniae strains.

V Tolun1, O Küçükbasmaci, D Törümküney-Akbulut, C Catal, M Anğ-Küçüker, O Anğ.   

Abstract

Resistance to fluoroquinolones has increased markedly since their introduction. Mechanisms of resistance to any antibiotic class might play a role in resistance to an unrelated antibiotic class. This study evaluated the relationship between extended-spectrum beta-lactamase (ESBL) production and ciprofloxacin resistance in Escherichia coli and Klebsiella pneumoniae strains isolated as causative agents of urinary tract infection. ESBL-producing strains were significantly more frequent among ciprofloxacin-resistant E. coli strains than among ciprofloxacin-susceptible E. coli strains (p = 0.015), but the difference was not significant among K. pneumoniae strains (p = 0.276).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706090     DOI: 10.1111/j.1469-0691.2004.00723.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  13 in total

1.  Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain.

Authors:  Aránzazu Valverde; Teresa M Coque; M Paz Sánchez-Moreno; Azucena Rollán; Fernando Baquero; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Molecular epidemiological analysis of Escherichia coli isolates producing extended-spectrum beta-lactamases for identification of nosocomial outbreaks in Stockholm, Sweden.

Authors:  Hong Fang; Christina Lundberg; Barbro Olsson-Liljequist; Göran Hedin; Emma Lindbäck; Asa Rosenberg; Johan Struwe
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

3.  In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.

Authors:  Lorenzo Drago; Lucia Nicola; Roberto Mattina; Elena De Vecchi
Journal:  BMC Microbiol       Date:  2010-04-21       Impact factor: 3.605

4.  Fluoroquinolone-resistant Escherichia coli, Indonesia.

Authors:  Kuntaman Kuntaman; Endang Sri Lestari; Juliëtte A Severin; Irma M Kershof; Ni Made Mertaniasih; Marijam Purwanta; Usman Hadi; James R Johnson; Alex van Belkum; Henri A Verbrugh
Journal:  Emerg Infect Dis       Date:  2005-09       Impact factor: 6.883

5.  Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Gaza Strip, Palestine.

Authors:  Zakaria El Astal
Journal:  J Biomed Biotechnol       Date:  2005

6.  Emergence of plasmid-mediated quinolone-resistant determinants in Klebsiella pneumoniae isolates from Tehran and Qazvin provinces, Iran.

Authors:  A Peymani; T Naserpour Farivar; L Nikooei; R Najafipour; A Javadi; A A Pahlevan
Journal:  J Prev Med Hyg       Date:  2015-08-05

7.  Evolution and Epidemiology of Multidrug-Resistant Klebsiella pneumoniae in the United Kingdom and Ireland.

Authors:  Danesh Moradigaravand; Veronique Martin; Sharon J Peacock; Julian Parkhill
Journal:  mBio       Date:  2017-02-21       Impact factor: 7.867

8.  Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital.

Authors:  Abdulrahman Abdulla Kader; Angamuthu Kumar
Journal:  Ann Saudi Med       Date:  2005 May-Jun       Impact factor: 1.526

9.  Mutant Prevention Concentration of Ciprofloxacin against Klebsiella pneumoniae Clinical Isolates: An Ideal Prognosticator in Treating Multidrug-Resistant Strains.

Authors:  B Aditi Priyadarshini; Krishnan Mahalakshmi; Venkatesan Naveen Kumar
Journal:  Int J Microbiol       Date:  2019-10-20

10.  Neonatal septicaemia caused by diverse clones of Klebsiella pneumoniae & Escherichia coli harbouring blaCTX-M-15.

Authors:  Subhasree Roy; Rajni Gaind; Harish Chellani; Srujana Mohanty; Saswati Datta; Arun K Singh; Sulagna Basu
Journal:  Indian J Med Res       Date:  2013-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.